#063 · Drug of the Day Isoxazole · Amanita muscaria Unscheduled (US federal) · GABAergic 2026-07-21

Muscimol

IUPAC: 5-(aminomethyl)-1,2-oxazol-3(2H)-one · 5-(aminomethyl)isoxazol-3-ol · C₄H₆N₂O₂ · MW 114.10 g/mol · CAS 2763-96-4 · ChEMBL CHEMBL273481

Muscimol (agarin, pantherine). The psychoactive isoxazole of Amanita muscaria (fly agaric) and A. pantherina (panther cap) — a conformationally locked structural analog of GABA and a potent DIRECT orthosteric agonist of the GABAA receptor. Unlike benzodiazepines, which are allosteric modulators that merely amplify GABA, muscimol binds the GABA orthosteric site itself and gates the channel — it is a switch, not a gain knob. Non-serotonergic: nothing to do with psilocybin. Sedative · dissociative · oneiric · deliriant at dose.

Primary target GABAA · orthosteric
Mechanism Direct agonist
GABAA Ki ~4–11 nM
Prodrug (in fungus) Ibotenic acid
Onset (oral) 30–120 min
Duration 4–10 h
Clearance Renal (largely unchanged)
Class GABAergic deliriant
01 · Mechanism of Action

Direct Orthosteric GABAA Agonism

Muscimol is the pharmacological opposite of a benzodiazepine. Where diazepam is a positive allosteric modulator that binds the α+/γ2 "benzodiazepine site" and does nothing without ambient GABA, muscimol binds the orthosteric GABA site itself — the two β+ interfaces of the pentamer — and activates the channel directly. It is a conformationally restricted bioisostere of GABA: the 3-isoxazolol ring is an anionic carboxylate surrogate and the aminomethyl group supplies the cationic amine, reproducing the zwitterionic pharmacophore of γ-aminobutyric acid but rigidly pre-organized. That rigidity is why muscimol binds GABAA with higher affinity than GABA itself (Ki in the low-nanomolar range) and behaves as a full — sometimes super-maximal — agonist at the synaptic receptor.

① Orthosteric Occupancy

Muscimol occupies the β+ orthosteric pocket where GABA normally binds — the aromatic box of β-Tyr/Phe residues and the arginine that anchors the carboxylate surrogate. This is the agonist site, not the allosteric BZD site diazepam and the "z-drugs" exploit.

② Direct Channel Gating

Occupancy triggers loop-C closure and the ECD→TMD conformational wave that opens the Cl⁻/HCO₃⁻ pore. Muscimol opens the channel on its own; it does not require endogenous GABA to be present. That is the core mechanistic contrast with every benzodiazepine.

③ Super-Affinity vs GABA

Because the isoxazole locks the bioactive conformation, muscimol pays little conformational-entropy penalty on binding — displacing [³H]GABA and [³H]muscimol at Ki ≈ 4–11 nM, tighter than GABA's own affinity. It is the canonical radioligand ([³H]muscimol) for mapping GABAA density.

④ Subtype Coverage

Muscimol is broadly active across αβγ synaptic subtypes (functional EC₅₀ ≈ 50–410 nM at α5/α3/α2 β2γ2) and at extrasynaptic δ-containing receptors that mediate tonic inhibition — the substrate of its heavy, "leaden" sedation. It is essentially non-selective across the GABAA family.

⑤ GABAA-ρ (partial)

At the homopentameric ρ (rho) subtype — historically "GABAC" — muscimol is a weaker partial agonist (EC₅₀ ≈ 0.7–1.4 µM). The 3D structure on the right (PDB 9G5Q) is exactly this ρ1 receptor caught with muscimol in the orthosteric pocket.

⑥ Not Serotonergic

Muscimol has no meaningful action at 5-HT2A or the serotonin system. This is the fault line with psilocybin/psilocin: Amanita intoxication is GABAergic sedation-dissociation, not a classic serotonergic psychedelic. Different receptor, different experience, different risks.

The behavioural signature follows from the pharmacology: broad, direct GABAA activation drives sedation, ataxia, myoclonic twitching, dysmetropsia (the "Alice-in-Wonderland" macropsia/micropsia), dreamlike (oneiric) and dissociative states, and anterograde amnesia. It is a depressant that reads as dissociative because the inhibition is deep and globally distributed rather than circuit-selective.

Muscimol → binds β⁺/α⁻ ORTHOSTERIC site (GABA site) → loop-C closure · ECD→TMD wave → Cl⁻ pore opens DIRECTLY → hyperpolarization ↑ · neuronal excitability ↓↓
Contrast — diazepam @ α⁺/γ2⁻ ALLOSTERIC site → only amplifies GABA that is already there (no GABA → no effect)
02 · Pharmacokinetics

Ibotenic Acid → Muscimol: a Prodrug That Cooks Itself

The pharmacology of a fly-agaric dose is really the pharmacology of two molecules. Fresh Amanita muscaria contains mostly ibotenic acid — a conformationally restricted glutamate analog that is an agonist at NMDA and other glutamate receptors, excitotoxic, and the chief source of the nausea, vomiting and delirium of raw-mushroom poisoning. Ibotenic acid is muscimol's prodrug: it undergoes decarboxylation (loss of CO₂) to muscimol on drying, aging, heating, or in the acidic stomach. Traditional preparation — drying the caps, gentle heating, or simmering — deliberately shifts the ibotenic-acid → muscimol ratio toward the sedative, less-toxic agonist. Raw or under-processed material is more emetic, more excitotoxic, and less predictable.

RouteOral (ingested fungus)
Onset (oral)30 – 120 min
Peak effect~2 – 3 h
Duration4 – 10 h
BBB penetrationYes (active CNS entry)
Primary eliminationRenal, largely unchanged
ProdrugIbotenic acid (−CO₂)
Content variabilityExtreme (cap/season/drying)

Conversion & clearance cascade: decarboxylation occurs largely before and during absorption; a substantial fraction of absorbed muscimol is then excreted intact in urine within hours.

Ibotenic acid
−CO₂ decarboxyl.
Muscimol ★
GABAA orthosteric
CNS effect
renal
Urine (unchanged)

Renal excretion of intact muscimol is the pharmacological basis of the well-documented Siberian folklore in which the urine of an intoxicated person (or reindeer) was consumed to recycle the active drug: muscimol survives first-pass and is passed largely unmetabolized, so the urine carries a cleaner, less-toxic dose than the raw mushroom (which is loaded with ibotenic acid). Not a recommendation — a mechanistic footnote that happens to be true.

Because dosing is governed by fungal chemistry, not a pill, exposure is inherently uncontrolled: muscimol and ibotenic-acid content vary several-fold between caps, populations, seasons, and drying methods. There is no reliable "standard dose" of a wild mushroom, and A. pantherina typically carries higher toxin loads than A. muscaria.

03 · Psychopharmacology · Why It Is Not a Psilocybin Trip

Sedative, Dissociative, Oneiric — and GABAergic to the Core

The subjective state produced by Amanita is categorically different from that of a serotonergic psychedelic. There is little of the visual geometry, ego dissolution, or emotional openness characteristic of psilocybin. Instead the profile is depressant and dissociative: waves of heavy sedation alternating with agitation, dreamlike lucid/semi-conscious episodes, distortions of size and distance, muscle twitching, and frequently amnesia for the peak. The mechanism is not mystery — it is deep, non-selective GABAA activation with an excitotoxic overlay from residual ibotenic acid.

Muscimol → Global Inhibitory Flood

Direct orthosteric agonism across synaptic (αβγ) and extrasynaptic (δ) GABAA receptors produces widespread cortical and subcortical inhibition — sedation, ataxia, hypnosis, anticonvulsant tone, and the dreamlike/oneiric quality. Tonic inhibition via δ-containing extrasynaptic receptors underwrites the "leaden," dissociative depth that distinguishes it from ordinary sedation.

Ibotenic Acid → Glutamatergic Excitation / Excitotoxicity

The un-decarboxylated fraction acts as an NMDA/glutamate-receptor agonist: nausea and vomiting, agitation, fasciculations and myoclonus, and — at high load — a hyperexcitable delirium and seizure risk. The clinical picture of raw-mushroom poisoning is this GABAergic-sedative / glutamatergic-excitatory tug-of-war, which is why presentations swing between somnolence and agitation.

Dysmetropsia & Oneiric State

Macropsia/micropsia and altered time and body perception (the literary "Alice-in-Wonderland" effects long linked to fly agaric), vivid dream-logic imagery, and lucid-dream-like intervals. This is perceptual distortion born of disrupted cortical gain control under heavy inhibition — not the structured serotonergic hallucinosis of a 5-HT2A agonist.

The Serotonin System Is Not Involved

No relevant 5-HT2A engagement, no serotonin-syndrome axis, no cross-tolerance with psilocybin/LSD. Categorizing Amanita with "magic mushrooms" is a pharmacological error with real consequences: the risk profile (sedation, delirium, respiratory-depressant synergy) is that of a GABAergic depressant, not a classic psychedelic. As a research tool, focal muscimol injection is used to reversibly silence a brain region — a chemical "off switch," the antithesis of a psychedelic.

Net: muscimol is best understood as a naturally occurring, orally active GABAA full agonist with a deliriant edge, delivered inside a mushroom that also contains an excitotoxic glutamate agonist. The experience is a sedative-dissociative-oneiric state whose character and hazards are set by GABAergic and glutamatergic pharmacology — and by how thoroughly the mushroom was dried and cooked.

04 · Harm Reduction

No Moralizing. The Pharmacology of Not Getting Hurt.

Evidence-based, non-judgmental. Amanita is not "just a mushroom high," and it is not a psilocybin mushroom. Its risks are dominated by ibotenic-acid toxicity, wildly variable potency, misidentification, and depressant synergy. Fatalities from muscimol/ibotenic alone are rare, but serious poisonings and dangerous combinations are not.

FATAL COMBINATIONS: Muscimol is a GABAA agonist — it deepens every other CNS depressant. ALCOHOL, BENZODIAZEPINES, BARBITURATES, GHB/GBL, OPIOIDS, gabapentinoids and sedating antihistamines all stack additively-to-synergistically → over-sedation, airway compromise, vomiting with a suppressed gag reflex (aspiration), and respiratory depression. If opioids are anywhere in the picture, carry naloxone. Do not combine with other sedatives; do not use alone. Verify every combination at TripSit Combo.

Ibotenic Acid & Delirium

  • Raw / under-dried mushrooms are high in ibotenic acid — an excitotoxin causing nausea, projectile vomiting, cramps, agitation, myoclonus, and true delirium
  • High load can cause seizures and hyperexcitable delirium, especially in children and with A. pantherina
  • Drying, aging and gentle cooking decarboxylate ibotenic acid → muscimol, reducing (not eliminating) the excitotoxic/GI burden
  • Presentation classically swings between deep sedation and agitation — do not assume a sleeping person is "fine"

Dose Variability & ID

  • Toxin content varies several-fold by cap, region, season and drying — there is no reliable dose in wild material
  • A. pantherina (panther cap) usually carries higher muscimol/ibotenic loads and causes more severe poisonings than A. muscaria
  • Misidentification kills: deadly amatoxin Amanita (A. phalloides, destroying angel) are lethal and can be confused by non-experts — a wrong ID is a liver transplant or a funeral
  • Commercial "Amanita gummies/extracts" are unregulated; labelled potency is frequently inaccurate or fabricated

Do Not Confuse With Psilocybin

  • This is not a magic mushroom: no serotonergic (5-HT2A) action, no cross-tolerance, an entirely different risk profile
  • Set/setting advice for psilocybin does not transfer — expect sedation, ataxia, amnesia and possible delirium, not a lucid psychedelic
  • It is a CNS depressant: driving, water, heights and machinery are dangerous during the sedative phase
  • GI upset is common even when well prepared; anti-emetic support and an empty stomach reduce (not remove) it

If Things Go Wrong

  • Serious poisoning is a medical emergency — persistent vomiting, seizures, severe agitation/delirium, or unresponsiveness need emergency care
  • There is no specific antidote; hospital treatment is supportive (airway, fluids, benzodiazepines for seizures/agitation under monitoring)
  • Bring or photograph the mushroom for identification; tell clinicians it may be Amanita so amatoxin poisoning can be excluded
  • Never mix with alcohol or other sedatives; have a sober sitter; do not use alone
3D Binding Pose · GABA-A orthosteric site PDB: 9G5Q
Loading structure from RCSB…
ρ1 pentamer (cartoon)
Orthosteric-pocket residues
Muscimol (A1IIN · ball-and-stick)
Structure: 9G5Q — cryo-EM of the human ρ1 (GABAA-ρ) receptor in complex with muscimol (chem-component A1IIN, "Muscimol") in the primed state, released 2025. A genuine muscimol co-complex: muscimol sits in the orthosteric GABA pocket of this homopentameric GABAA-family channel. Honest label — this is the homomeric ρ1 subtype (where muscimol is a partial agonist), not the synaptic α1β2γ2 heteropentamer, but it captures muscimol bound at the very agonist site described above. Rotate · scroll to zoom · right-drag to translate.
View on RCSB →

Binding & Functional Affinities

Muscimol
Target Affinity Rel. Action
GABAA (rat)
[³H]GABA displacement · brain
Ki = 4 nM
JMC 1980
Agonist
GABAA (human)
[³H]GABA displ. · cerebellum
Ki = 11 nM
JMC 1980
Agonist
GABAA
[³H]muscimol self-displ.
Ki = 6–7 nM
JMC 2013 / EJMC 2014
Agonist
α5β2γ2
GABAA · functional (FLIPR)
EC₅₀ = 54 nM
JMC 2013
Full agonist
α3β2γ2
GABAA · functional (FLIPR)
EC₅₀ = 210 nM
JMC 2013
Full agonist
GABAA-ρ1
homopentamer (PDB 9G5Q subtype)
EC₅₀ = 0.7–1.4 µM
JMC 2008/2013
Partial agonist
Source: ChEMBL CHEMBL273481 (muscimol). Binding Ki = radioligand displacement at native GABAA (Krogsgaard-Larsen, J Med Chem 1980; later [³H]muscimol datasets J Med Chem 2013, Eur J Med Chem 2014). Functional EC₅₀ = human recombinant subtypes, FLIPR (J Med Chem 2013); ρ1 EC₅₀ from J Med Chem 2008/2013. Rel. bars scale inversely with Ki/EC₅₀ (higher bar = higher potency); binding and functional metrics shown together for context.

ΔS · Entropy-Docking Note

FlexAID∆S
Muscimol is the textbook case of entropy-driven affinity by pre-organization. GABA is a floppy, freely-rotating chain that must fold into a single compact bioactive conformation to fit the β+ orthosteric pocket — paying a steep conformational-entropy penalty (−TΔSconf > 0) out of its own free-energy budget on binding. Muscimol hard-wires that same zwitterionic geometry into a rigid isoxazole ring (RTB = 1): the carboxylate-surrogate and the aminomethyl amine are locked at the correct distance and angle before it ever reaches the pocket. It therefore forfeits almost none of its ligand conformational entropy on docking, so more of the ΔG = ΔH − TΔS ledger is retained as net binding free energy — the physical reason a rigid GABA-mimetic out-binds GABA itself (Ki ≈ 4–11 nM vs GABA's higher values). In the FlexAID∆S picture the discriminating term is exactly this ΔSconf collapse: a low-flexibility ligand pays little, converts orthosteric occupancy directly into pore-open probability, and gates the channel — while a benzodiazepine, docking to a different (allosteric) pocket, buys leverage over the receptor's conformational entropy rather than a ligand-side entropy bargain. Same superfamily, opposite thermodynamic strategy.